# Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients

Study · id `cardio:ct-nct04830449` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04830449](<https://clinicaltrials.gov/study/NCT04830449>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04830449

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 122 participants.

## Technical summary

Registry record NCT04830449. Randomized; double masking; primary purpose treatment. Start 2020-10-29 (actual); primary completion 2021-08-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 122 participants (enrolled count; ClinicalTrials.gov record NCT04830449, source copy `cardio:ctgov-nct04830449-2023-09-22`, retrieved 2026-10-26)
- Started: 2020-10-29 (actual) (ClinicalTrials.gov record NCT04830449, source copy `cardio:ctgov-nct04830449-2023-09-22`, retrieved 2026-10-26)
- Primary completion: 2021-08-24 (actual) (ClinicalTrials.gov record NCT04830449, source copy `cardio:ctgov-nct04830449-2023-09-22`, retrieved 2026-10-26)
- Completion: 2021-08-24 (actual) (ClinicalTrials.gov record NCT04830449, source copy `cardio:ctgov-nct04830449-2023-09-22`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04830449, source copy `cardio:ctgov-nct04830449-2023-09-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04830449-2023-09-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients
- Condition: Hypertension
- Intervention (Drug): HCP1904-2
- Intervention (Drug): RLD2001-2
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

## Provenance

Content hash: 8936ef432d6f6b0d0f5ca6452ecdcbfd22712654226b10fb2e3d2ed38d62cb72
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
